138 related articles for article (PubMed ID: 16945014)
1. Enzyme fragment complementation binding assay for p38alpha mitogen-activated protein kinase to study the binding kinetics of enzyme inhibitors.
Zaman GJ; van der Lee MM; Kok JJ; Nelissen RL; Loomans EE
Assay Drug Dev Technol; 2006 Aug; 4(4):411-20. PubMed ID: 16945014
[TBL] [Abstract][Full Text] [Related]
2. The design, synthesis, and evaluation of 8 hybrid DFG-out allosteric kinase inhibitors: a structural analysis of the binding interactions of Gleevec, Nexavar, and BIRB-796.
Dietrich J; Hulme C; Hurley LH
Bioorg Med Chem; 2010 Aug; 18(15):5738-48. PubMed ID: 20621496
[TBL] [Abstract][Full Text] [Related]
3. Analysis of imatinib and sorafenib binding to p38alpha compared with c-Abl and b-Raf provides structural insights for understanding the selectivity of inhibitors targeting the DFG-out form of protein kinases.
Namboodiri HV; Bukhtiyarova M; Ramcharan J; Karpusas M; Lee Y; Springman EB
Biochemistry; 2010 May; 49(17):3611-8. PubMed ID: 20337484
[TBL] [Abstract][Full Text] [Related]
4. Fluorescence polarization binding assay to develop inhibitors of inactive p38alpha mitogen-activated protein kinase.
Munoz L; Selig R; Yeung YT; Peifer C; Hauser D; Laufer S
Anal Biochem; 2010 Jun; 401(1):125-33. PubMed ID: 20175985
[TBL] [Abstract][Full Text] [Related]
5. Tetra-substituted pyridinylimidazoles as dual inhibitors of p38α mitogen-activated protein kinase and c-Jun N-terminal kinase 3 for potential treatment of neurodegenerative diseases.
Muth F; Günther M; Bauer SM; Döring E; Fischer S; Maier J; Drückes P; Köppler J; Trappe J; Rothbauer U; Koch P; Laufer SA
J Med Chem; 2015 Jan; 58(1):443-56. PubMed ID: 25475894
[TBL] [Abstract][Full Text] [Related]
6. Design and synthesis of novel p38α MAP kinase inhibitors: discovery of pyrazole-benzyl ureas bearing 2-molpholinopyrimidine moiety.
Arai T; Ohno M; Inoue H; Hayashi S; Aoki T; Hirokawa H; Meguro H; Koga Y; Oshida K; Kainoh M; Suyama K; Kawai H
Bioorg Med Chem Lett; 2012 Aug; 22(15):5118-22. PubMed ID: 22749282
[TBL] [Abstract][Full Text] [Related]
7. Molecular dynamics simulation and free energy calculation studies of the binding mechanism of allosteric inhibitors with p38α MAP kinase.
Yang Y; Shen Y; Liu H; Yao X
J Chem Inf Model; 2011 Dec; 51(12):3235-46. PubMed ID: 22097958
[TBL] [Abstract][Full Text] [Related]
8. Pyridinyl imidazole inhibitors of p38 mitogen-activated protein kinase bind in the ATP site.
Young PR; McLaughlin MM; Kumar S; Kassis S; Doyle ML; McNulty D; Gallagher TF; Fisher S; McDonnell PC; Carr SA; Huddleston MJ; Seibel G; Porter TG; Livi GP; Adams JL; Lee JC
J Biol Chem; 1997 May; 272(18):12116-21. PubMed ID: 9115281
[TBL] [Abstract][Full Text] [Related]
9. High-content screening analysis of the p38 pathway: profiling of structurally related p38alpha kinase inhibitors using cell-based assays.
Ross S; Chen T; Yu V; Tudor Y; Zhang D; Liu L; Tamayo N; Dominguez C; Powers D
Assay Drug Dev Technol; 2006 Aug; 4(4):397-409. PubMed ID: 16945013
[TBL] [Abstract][Full Text] [Related]
10. The design, synthesis and potential utility of fluorescence probes that target DFG-out conformation of p38alpha for high throughput screening binding assay.
Tecle H; Feru F; Liu H; Kuhn C; Rennie G; Morris M; Shao J; Cheng AC; Gikunju D; Miret J; Coli R; Xi SH; Clugston SL; Low S; Kazmirski S; Ding YH; Cao Q; Johnson TL; Deshmukh GD; DiNitto JP; Wu JC; English JM
Chem Biol Drug Des; 2009 Dec; 74(6):547-59. PubMed ID: 19843080
[TBL] [Abstract][Full Text] [Related]
11. Discovery and characterization of MAPK-activated protein kinase-2 prevention of activation inhibitors.
Cumming JG; Debreczeni JÉ; Edfeldt F; Evertsson E; Harrison M; Holdgate GA; James MJ; Lamont SG; Oldham K; Sullivan JE; Wells SL
J Med Chem; 2015 Jan; 58(1):278-93. PubMed ID: 25255283
[TBL] [Abstract][Full Text] [Related]
12. Fluorescence polarization-based assays for detecting compounds binding to inactive c-Jun N-terminal kinase 3 and p38α mitogen-activated protein kinase.
Ansideri F; Lange A; El-Gokha A; Boeckler FM; Koch P
Anal Biochem; 2016 Jun; 503():28-40. PubMed ID: 26954235
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis and anti-inflammatory activity of imidazol-5-yl pyridine derivatives as p38α/MAPK14 inhibitor.
Ali EMH; Abdel-Maksoud MS; Hassan RM; Mersal KI; Ammar UM; Se-In C; He-Soo H; Kim HK; Lee A; Lee KT; Oh CH
Bioorg Med Chem; 2021 Feb; 31():115969. PubMed ID: 33422910
[TBL] [Abstract][Full Text] [Related]
14. Human p38α mitogen-activated protein kinase in the Asp168-Phe169-Gly170-in (DFG-in) state can bind allosteric inhibitor Doramapimod.
Suplatov D; Kopylov K; Sharapova Y; Švedas V
J Biomol Struct Dyn; 2019 May; 37(8):2049-2060. PubMed ID: 29749295
[TBL] [Abstract][Full Text] [Related]
15. Development of a fluorescent-tagged kinase assay system for the detection and characterization of allosteric kinase inhibitors.
Simard JR; Getlik M; Grütter C; Pawar V; Wulfert S; Rabiller M; Rauh D
J Am Chem Soc; 2009 Sep; 131(37):13286-96. PubMed ID: 19572644
[TBL] [Abstract][Full Text] [Related]
16. The activation state of p38 mitogen-activated protein kinase determines the efficiency of ATP competition for pyridinylimidazole inhibitor binding.
Frantz B; Klatt T; Pang M; Parsons J; Rolando A; Williams H; Tocci MJ; O'Keefe SJ; O'Neill EA
Biochemistry; 1998 Sep; 37(39):13846-53. PubMed ID: 9753474
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis, biological evaluation, and docking studies of novel (imidazol-5-yl)pyrimidine-based derivatives as dual BRAF
Ali EMH; El-Telbany RFA; Abdel-Maksoud MS; Ammar UM; Mersal KI; Zaraei SO; El-Gamal MI; Choi SI; Lee KT; Kim HK; Lee KH; Oh CH
Eur J Med Chem; 2021 Apr; 215():113277. PubMed ID: 33601311
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and evaluation of the epithelial-to- mesenchymal inhibitory activity of indazole-derived imidazoles as dual ALK5/p38α MAP inhibitors.
Liu YY; Guo Z; Wang JY; Wang HM; Da Qi J; Ma J; Piao HR; Jin CH; Jin X
Eur J Med Chem; 2021 Apr; 216():113311. PubMed ID: 33677350
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site.
Pargellis C; Tong L; Churchill L; Cirillo PF; Gilmore T; Graham AG; Grob PM; Hickey ER; Moss N; Pav S; Regan J
Nat Struct Biol; 2002 Apr; 9(4):268-72. PubMed ID: 11896401
[TBL] [Abstract][Full Text] [Related]
20. Switch control pocket inhibitors of p38-MAP kinase. Durable type II inhibitors that do not require binding into the canonical ATP hinge region.
Ahn YM; Clare M; Ensinger CL; Hood MM; Lord JW; Lu WP; Miller DF; Patt WC; Smith BD; Vogeti L; Kaufman MD; Petillo PA; Wise SC; Abendroth J; Chun L; Clark R; Feese M; Kim H; Stewart L; Flynn DL
Bioorg Med Chem Lett; 2010 Oct; 20(19):5793-8. PubMed ID: 20800479
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]